益生菌辅助治疗幽门螺杆菌感染的研究进展

Research Progress of Probiotics in the Adjuvant Therapy of Helicobacter pylori Infections

摘要:

幽门螺杆菌（Helicobacter pylori， Hp）是一种定植在人体胃部可诱发胃炎、胃溃疡甚至胃癌的关键致病菌。目前，临床上通常采用抗生素结合质子泵抑制剂或铋剂的三联或四联疗法治疗Hp感染。然而，由于Hp对抗生素的耐药性不断上升，使得抗生素的治疗效果逐渐减弱，并且单一疗法的Hp根除率不足80%。研究发现，益生菌在辅助治疗Hp感染方面具有较好的效果，不仅能够减轻Hp导致的胃部炎症，提高Hp根除率，还能降低抗生素治疗的副作用。作者进一步综述了益生菌在治疗Hp感染中的应用，为益生菌辅助治疗的研究与临床应用提供参考。

Abstract:

Helicobacter pylori (Hp) is a major pathogenic bacterium that infects the human stomach and can lead to various gastrointestinal disorders, including gastritis, gastric ulcers, and even gastric cancer. Currently, triple or quadruple therapy combining antibiotics with proton pump inhibitors or bismuth compounds is commonly used to treat Hp infections in clinical practice. However, the escalating antibiotic resistance of Hp has led to a gradual reduction in the effectiveness of antibiotic treatments, with monotherapy having an eradication rate of less than 80%. Recent studies have found that probiotics show promising results in the adjuvant therapy for Hp infections. They not only alleviate gastric inflammation caused by Hp but also enhance the eradication rate of Hp and reduce the side effects of antibiotic treatment. The author reviews the application of probiotics in the treatment of Hp infections, aiming to provide a reference for further research and clinical use of probiotics as an adjuvant therapy.